LB-102 for Schizophrenia
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.
Who Is on the Research Team?
John Kane, MD
Principal Investigator
The Zucker Hillside Hospital
Are You a Good Fit for This Trial?
This trial is for adults with acute schizophrenia experiencing a worsening of symptoms. Participants must have a diagnosis of schizophrenia and be currently experiencing an acute episode to qualify.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive LB-102 or placebo for 28 days to evaluate antipsychotic efficacy and safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LB-102
Find a Clinic Near You
Who Is Running the Clinical Trial?
LB Pharmaceuticals Inc.
Lead Sponsor